Last reviewed · How we verify
Sin-Bev-TACE
Sin-Bev-TACE is a combination therapy that pairs bevacizumab (anti-VEGF monoclonal antibody) with transarterial chemoembolization (TACE) to inhibit tumor angiogenesis while delivering chemotherapy directly to hepatic tumors.
Sin-Bev-TACE is a combination therapy that pairs bevacizumab (anti-VEGF monoclonal antibody) with transarterial chemoembolization (TACE) to inhibit tumor angiogenesis while delivering chemotherapy directly to hepatic tumors. Used for Hepatocellular carcinoma (HCC), intermediate to advanced stage.
At a glance
| Generic name | Sin-Bev-TACE |
|---|---|
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University |
| Drug class | Anti-angiogenic monoclonal antibody combined with chemoembolization |
| Target | VEGF (vascular endothelial growth factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab blocks vascular endothelial growth factor (VEGF) signaling to prevent new blood vessel formation that tumors depend on for growth. When combined with TACE—a minimally invasive procedure that delivers chemotherapy directly into the hepatic artery feeding the tumor while occluding blood flow—the dual mechanism targets both tumor vasculature and tumor cells directly, potentially improving efficacy in hepatocellular carcinoma.
Approved indications
- Hepatocellular carcinoma (HCC), intermediate to advanced stage
Common side effects
- Hypertension
- Proteinuria
- Bleeding
- Hepatic dysfunction
- Fatigue
Key clinical trials
- Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC (PHASE3)
- TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sin-Bev-TACE CI brief — competitive landscape report
- Sin-Bev-TACE updates RSS · CI watch RSS
- Second Affiliated Hospital of Guangzhou Medical University portfolio CI